The content discusses the potential approval of blood-based biomarker tests for colorectal cancer (CRC) screening by US regulators. Various companies, including Guardant Health, Inc, CellMax Life, Freenome, and Exact Sciences, are developing blood tests for CRC. The shift towards noninvasive tests could impact the prevalence of screening colonoscopies. However, past disappointments with CRC blood tests and the necessity of follow-up diagnostic procedures post-positive results are highlighted. The article also delves into the challenges of gaining FDA approval, Medicare coverage, and USPSTF recommendations for CRC blood tests.
Başka Bir Dile
kaynak içeriğinden
www.medscape.com
Önemli Bilgiler Şuradan Elde Edildi
by Kerry Dooley... : www.medscape.com 04-05-2023
https://www.medscape.com/viewarticle/990465Daha Derin Sorular